Top Research Reports for JPMorgan, Gilead Sciences & CSX
Gilead launches combination HIV pill in UK and Germany - PMLiVE
Gilead's Truvada faces Teva generics assault amid Descovy switching campaign | Fierce Pharma
Gilead to Slice List Prices of Liver Drugs - WSJ
Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut
Gilead reports reduced mortality risk with remdesivir for Covid-19
Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back | Fierce Pharma
Gilead bags EU approval for next-generation HIV drug - PMLiVE
Gilead says generic Truvada will be available in 2020
United States v. Gilead: The Fight for PrEP | Bill of Health
Gilead reports 3% revenue growth in Q1 2022
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine - Los Angeles Times
PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health News : NPR
Huffington Post Op-ed: Gilead Sciences: Price Gouger, Tax Dodger - Americans For Tax Fairness
Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers :: Pink Sheet
Gilead Will Begin Marketing Lower Cost Hepatitis C Drugs in January – RWC-340B
Gilead Sciences, Inc.
Gilead's COVID-19 antiviral Veklury blew past sales estimates in late 2021 as omicron surged, vaccinations lagged | Fierce Pharma
Federal government sues Gilead Sciences, alleging patent infringement on HIV drugs
Gilead Revenue Soars on Hepatitis C Drug - The New York Times
New Data On Gilead's Covid-19 Drug Is Positive, but Inconclusive | Barron's
Change to Gilead assistance program threatens PrEP access, HIV advocates say | PBS NewsHour
A Drug is 90 Percent Effective at Preventing HIV.… | Arnold Ventures
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention - The New York Times
Pharma giant Gilead sued for 'withholding' safer HIV drug | PinkNews
Global shortage of key Covid drug leads to NHS rationing | Coronavirus | The Guardian
Generic HIV prevention drug coming in 2020, Gilead says
Gilead prices remdesivir at $2,340 per patient for developed countries
